Study of the Disease Process of Lymphangioleiomyomatosis
NCT: NCT00001465 · RECRUITING
Brief Summary
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
Frequently Asked Questions
What is Study of the Disease Process of Lymphangioleiomyomatosis?
Study of the Disease Process of Lymphangioleiomyomatosis is a clinical trial registered under NCT00001465. Current status: RECRUITING.
What is the status of NCT00001465?
The current status of NCT00001465 (Study of the Disease Process of Lymphangioleiomyomatosis) is: RECRUITING.
When did Study of the Disease Process of Lymphangioleiomyomatosis start?
Study of the Disease Process of Lymphangioleiomyomatosis started on 1995-12-18.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.